| |
HIV+ Study of Vaccine Response in Immunocompromised - Immunocompromised Response to COVID-19 Vaccination
|
| |
| |
https://www.upmc.com/media/news/063021-haidar-covics-interim-medrxiv
Download the PDF
6/30/2021
PITTSBURGH - People with conditions that compromise their immune systems exhibit a wide spectrum of antibody responses to COVID-19 vaccination, ranging from only 1 in 5 lung transplant patients having an antibody response to a nearly complete response in patients with well-controlled HIV. The results are part of an interim analysis of a large study on UPMC patients and health care workers.
The study is one of the first to verify that the ability of blood from immunocompromised participants to neutralize the virus closely mirrors their antibody levels measured by a Food and Drug Administration (FDA)-approved test, meaning that antibody testing is a good proxy for neutralizing titers.
In an effort to share crucial information to guide clinical and public health decisions, UPMC and University of Pittsburgh School of Medicine physician-scientists published the findings today in medRxiv, a preprint journal, and announced the results ahead of peer-reviewed publication. [not peer-reviewed]
from U of Pittsburg study paper:
"...In this prospective, longitudinal study of immunocompromised patients who have completed their COVID-19 vaccine series, we found that compared to healthy HCW, seropositivity was much lower in SOT recipients and patients with hematologic cancers
(37.2% and 54.7%, respectively). In contrast, seropositivity among patients with solid neoplasms and autoimmune conditions approached those of HCW though remained lower (over 80% each versus 98.1%, respectively). Importantly, well-controlled patients
with HIV mounted antibody responses nearly identical to those of healthy HCW. SARS-CoV-2 neutralization titers were generally proportional to antibody levels, though larger studies will be needed to fully assess whether subsets of immunocompromised patients fail to neutralize the virus. Finally, even among immunocompromised patients, some individuals mounted both antibody levels and neutralization capabilities that matched those of healthy HCW......Seropositivity. Compared to HCWs of whom 98.1% [93.4%-99.8%] were seropositive, seropositivity was significantly lower
among persons with SOT (37.2% [30.1%-44.6%], p<.001), hematological malignancies (54.7% [42.7%-66.2%], p<.001), solid tumors (82.4% [65.5%-93.2%], p=.009), and autoimmune/chronic inflammatory conditions (83.8% [77.1%-89.1%], p<.001), (Figure 1). In
contrast, there was no difference in seropositivity between healthy HCW and patients with HIV (94.6% [81.2%-99.3%], p = 0.26), all
of whom were receiving antiviral therapy, had undetectable viral loads, and CD4 counts > 200 cell/mm3. There was no association
between time from vaccination and seropsitivity. Unadjusted risk factors for seronegativity after vaccination are shown in Table 2. Overall, age > 44 and male
sex were associated with failure to produce SARS-CoV-2 antibodies.."
"Our study highlights the urgent need to optimize and individualize COVID-19 prevention in patients with immunocompromising conditions and have other treatments-such as monoclonal antibodies-available should vaccination fail," said lead author Ghady Haidar, M.D., UPMC transplant infectious diseases physician and assistant professor in Pitt's Division of Infectious Diseases. "Given the Centers for Disease Control and Prevention's recommendations permitting vaccinated people to abandon masking and social distancing in most settings, our findings also have implications for public health guidance, since nearly 4% of Americans are immunocompromised."
Between April 14 and June 14, the UPMC-Pitt team tested blood samples from 107 healthy volunteer health care workers and 489 immunocompromised patients who had completed COVID-19 vaccination as part of the COVID-19 Vaccine in the Immunocompromised Study (CoVICS). The immunocompromised patients included those who had a solid organ transplant, an autoimmune disorder, blood cancer, a solid tumor cancer or HIV.
Antibodies are proteins that block invading pathogens-such as SARS-CoV-2, the virus that causes COVID-19-from infecting cells. They are produced by the immune system in response to vaccination.
While 98.1% of the health care workers produced antibodies after vaccination, only 37.2% of the vaccinated solid organ transplant patients were positive for antibodies; 54.7% of the blood cancer patients; 82.4% of those with solid tumor cancer and 83.8% of patients with autoimmune disorders. In contrast, 94.6% of patients with HIV made antibodies.
Among patients with solid organ transplants, lung transplant patients had a particularly poor response to vaccination, with only 22.2% producing antibodies. Liver transplant patients fared best, with 60.6% of study participants producing antibodies after vaccination. Patients who received their transplant less than a year ago were less likely to respond to vaccination than those transplanted earlier.
In addition, cancer patients receiving radiation therapy and patients taking certain medications-such as antimetabolites for transplant and anti-CD20 monoclonal antibodies for autoimmune disorders-were more likely not to produce antibodies after COVID-19 vaccination.
The researchers then took blood sera, the amber-colored, protein-rich liquid that separates out when blood coagulates, from a subset of the participants-30 health care workers and 36 immunocompromised patients-and tested it for its ability to neutralize SARS-CoV-2 pseudovirus. They found that the ability of the participants' sera to neutralize the virus correlated strongly with their antibody levels measured by an independent FDA-approved test.
"This is important because we've seen several studies indicating that immunocompromised people are less likely to produce antibodies in response to COVID-19 vaccination," said senior author John Mellors, M.D., chief of the Division of Infectious Diseases at UPMC and Distinguished Professor of Medicine at Pitt. "And we can assume this means they're less likely to be able to fight the virus, but until we were able to test for virus neutralization, that was only an assumption. Our results give us more confidence in saying that people who do not produce antibodies truly are at greater risk of COVID-19 infection and that the level of antibodies produced is a proxy for ability to neutralize the virus."
However, the physician-scientists stressed that the immune system has more tools than antibodies at its disposal, including T-cells and other immune cells, which may provide some level of immunity. So, while it is concerning when someone gets a negative antibody test, it is still possible for the immune system to fight off the virus, even if vaccination does not produce antibodies, Mellors said.
The Centers for Disease Control and Prevention, FDA, American Society of Transplantation and several national cancer associations, among others, recommend against routine antibody testing after vaccination, and UPMC currently does not offer it outside of a research study or clinical indication.
"At this point, clinical advice does not change for immunocompromised people, whether an antibody test is positive or negative," said Haidar. "They should still wear a mask in public, practice social distancing, get vaccinated and encourage those around them to be vaccinated. A positive antibody test does not give us certainty that they are protected against the virus, and the risk of COVID-19 causing serious complications and death still exists."
|
|
| |
| |
|
|
|
